Dear stakeholders,
For information, the company have advised that they are no longer pursuing a Marketing Authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA) for this indication at this time. Therefore, NICE has decided to suspend this evaluation from its current work programme.
| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Reason for decision | Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources |
| Further information | Dear stakeholders, For information, the company have advised that they are no longer pursuing a Marketing Authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA) for this indication at this time. Therefore, NICE has decided to suspend this evaluation from its current work programme. |
| Process | STA Standard |
| ID number | 12088 |
Project Team
| Project lead | Danielle Lees |
Email enquiries
- If you have any queries please email topic.selection@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 11 February 2025 | Suspended |
| 10 February 2025 | Discontinued. Dear stakeholders, For information, the company have advised that they are no longer pursuing a Marketing Authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA) for this indication at this time. Therefore, NICE has decided to suspend this evaluation from its current work programme. |
For further information on our processes and methods, please see our CHTE processes and methods manual